Catalyst Pharmaceuticals Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals will be holding an earnings conference call on Monday, March 15th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Monday, November, 16th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. The biopharmaceutical company had revenue of $29.32 million for the quarter, compared to analyst estimates of $31.22 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.04% and a net margin of 60.48%.
View Catalyst Pharmaceuticals' earnings history.

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 0.0% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 1-year price objectives for Catalyst Pharmaceuticals' shares. Their forecasts range from $5.50 to $10.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $7.83 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Catalyst Pharmaceuticals include uniQure (QURE), Five Prime Therapeutics (FPRX), COMPASS Pathways (CMPS), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPD), Ocular Therapeutix (OCUL), Cytokinetics (CYTK), Nkarta (NKTX), Supernus Pharmaceuticals (SUPN), Zealand Pharma A/S (ZEAL), Phathom Pharmaceuticals (PHAT), DiaMedica Therapeutics (DMCAF), Constellation Pharmaceuticals (CNST), Rhythm Pharmaceuticals (RYTM) and Theravance Biopharma (TBPH).
View all of CPRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.47%), Royce & Associates LP (2.32%), HealthInvest Partners AB (1.69%), Northern Trust Corp (1.21%), Nuveen Asset Management LLC (0.88%) and Schroder Investment Management Group (0.88%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals.

CPRX stock was sold by a variety of institutional investors in the last quarter, including Engineers Gate Manager LP, Jane Street Group LLC, Schroder Investment Management Group, Credit Suisse AG, SG Americas Securities LLC, Brandywine Global Investment Management LLC, Northern Trust Corp, and Wells Fargo & Company MN.
View insider buying and selling activity for Catalyst Pharmaceuticals or view top insider-selling stocks.

CPRX stock was purchased by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, Royce & Associates LP, Nuveen Asset Management LLC, Globeflex Capital L P, BlackRock Inc., Prairiewood Capital LLC, Bank of New York Mellon Corp, and GSA Capital Partners LLP. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals or or view top insider-buying stocks.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $3.52.

Catalyst Pharmaceuticals has a market capitalization of $364.84 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis.

Catalyst Pharmaceuticals employs 76 workers across the globe.

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]